255 related articles for article (PubMed ID: 14746840)
1. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma.
Anderson CD; Rice MH; Pinson CW; Chapman WC; Chari RS; Delbeke D
J Gastrointest Surg; 2004 Jan; 8(1):90-7. PubMed ID: 14746840
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer.
Corvera CU; Blumgart LH; Akhurst T; DeMatteo RP; D'Angelica M; Fong Y; Jarnagin WR
J Am Coll Surg; 2008 Jan; 206(1):57-65. PubMed ID: 18155569
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma.
Kim YJ; Yun M; Lee WJ; Kim KS; Lee JD
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1467-72. PubMed ID: 14579085
[TBL] [Abstract][Full Text] [Related]
4. The role of (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma.
Moon CM; Bang S; Chung JB
Surg Oncol; 2011 Mar; 20(1):e10-7. PubMed ID: 19804967
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.
Kluge R; Schmidt F; Caca K; Barthel H; Hesse S; Georgi P; Seese A; Huster D; Berr F
Hepatology; 2001 May; 33(5):1029-35. PubMed ID: 11343227
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
[TBL] [Abstract][Full Text] [Related]
8. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
Kim JY; Kim MH; Lee TY; Hwang CY; Kim JS; Yun SC; Lee SS; Seo DW; Lee SK
Am J Gastroenterol; 2008 May; 103(5):1145-51. PubMed ID: 18177454
[TBL] [Abstract][Full Text] [Related]
9. FDG PET in the diagnosis of hilar cholangiocarcinoma.
Fritscher-Ravens A; Bohuslavizki KH; Broering DC; Jenicke L; Schäfer H; Buchert R; Rogiers X; Clausen M
Nucl Med Commun; 2001 Dec; 22(12):1277-85. PubMed ID: 11711897
[TBL] [Abstract][Full Text] [Related]
10. Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer.
Lee JY; Kim HJ; Yim SH; Shin DS; Yu JH; Ju DY; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
Korean J Gastroenterol; 2013 Oct; 62(4):227-33. PubMed ID: 24162710
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma.
Lee SW; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol; 2010 May; 45(5):560-6. PubMed ID: 20035356
[TBL] [Abstract][Full Text] [Related]
12. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
13. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.
Petrowsky H; Wildbrett P; Husarik DB; Hany TF; Tam S; Jochum W; Clavien PA
J Hepatol; 2006 Jul; 45(1):43-50. PubMed ID: 16690156
[TBL] [Abstract][Full Text] [Related]
14. Value of PET/CT in the management of primary hepatobiliary tumors, part 2.
Sacks A; Peller PJ; Surasi DS; Chatburn L; Mercier G; Subramaniam RM
AJR Am J Roentgenol; 2011 Aug; 197(2):W260-5. PubMed ID: 21785051
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Performance and Prognostic Relevance of FDG Positron Emission Tomography/Computed Tomography for Patients with Extrahepatic Cholangiocarcinoma.
Kim NH; Lee SR; Kim YH; Kim HJ
Korean J Radiol; 2020 Dec; 21(12):1355-1366. PubMed ID: 32767862
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography and cholangiocarcinoma in primary sclerosing cholangitis.
Widjaja A; Mix H; Wagner S; Graz KF; van den Hoff J; Petrich T; Meier PN; Manns MP
Z Gastroenterol; 1999 Aug; 37(8):731-3. PubMed ID: 10494608
[TBL] [Abstract][Full Text] [Related]
18. FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma.
Ruys AT; Bennink RJ; van Westreenen HL; Engelbrecht MR; Busch OR; Gouma DJ; van Gulik TM
HPB (Oxford); 2011 Apr; 13(4):256-62. PubMed ID: 21418131
[TBL] [Abstract][Full Text] [Related]
19. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer.
Park MS; Lee SM
Anticancer Res; 2014 May; 34(5):2551-4. PubMed ID: 24778075
[TBL] [Abstract][Full Text] [Related]
20. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer.
Kato T; Tsukamoto E; Kuge Y; Katoh C; Nambu T; Nobuta A; Kondo S; Asaka M; Tamaki N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1047-54. PubMed ID: 12173019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
